Ligand Pharmaceuticals (LGND) Expected to Announce Quarterly Earnings on Thursday

07 May 2026, 03:28 by Doug Wharley · The Cerbat Gem

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Ligand Pharmaceuticals to post earnings of $1.84 per share and revenue of $59.0990 million for the quarter. Ligand Pharmaceuticals has set its FY 2026 guidance at 8.000-9.000 EPS. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.56. The firm had revenue of $59.67 million for the quarter, compared to the consensus estimate of $55.59 million. Ligand Pharmaceuticals had a return on equity of 13.86% and a net margin of 46.42%.The firm’s quarterly revenue was up 39.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.27 EPS. On average, analysts expect Ligand Pharmaceuticals to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Ligand Pharmaceuticals Trading Up 0.1%

NASDAQ:LGND opened at $232.55 on Thursday. The stock’s 50 day moving average price is $211.74 and its 200 day moving average price is $200.35. The company has a market capitalization of $4.66 billion, a PE ratio of 39.89, a P/E/G ratio of 1.68 and a beta of 1.20. The company has a quick ratio of 21.98, a current ratio of 22.23 and a debt-to-equity ratio of 0.44. Ligand Pharmaceuticals has a 52-week low of $98.89 and a 52-week high of $247.38.

Insider Transactions at Ligand Pharmaceuticals

In other Ligand Pharmaceuticals news, Director Stephen L. Sabba sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $207.87, for a total transaction of $207,870.00. Following the sale, the director owned 32,793 shares in the company, valued at $6,816,680.91. This represents a 2.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Andrew Reardon sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $231.31, for a total value of $1,156,550.00. Following the sale, the insider owned 41,382 shares in the company, valued at $9,572,070.42. The trade was a 10.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 35,448 shares of company stock worth $7,450,977. 7.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ligand Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. CIBC Private Wealth Group LLC grew its holdings in Ligand Pharmaceuticals by 86.3% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company’s stock worth $26,000 after buying an additional 69 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Ligand Pharmaceuticals during the 4th quarter worth $31,000. JPL Wealth Management LLC bought a new stake in shares of Ligand Pharmaceuticals during the 3rd quarter worth $52,000. Persistent Asset Partners Ltd bought a new stake in shares of Ligand Pharmaceuticals during the 4th quarter worth $150,000. Finally, State of Wyoming acquired a new stake in shares of Ligand Pharmaceuticals in the fourth quarter worth $169,000. 91.28% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Royal Bank Of Canada raised their price target on Ligand Pharmaceuticals from $235.00 to $252.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 28th. HC Wainwright lifted their price objective on Ligand Pharmaceuticals from $243.00 to $289.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Citigroup raised their price target on Ligand Pharmaceuticals from $276.00 to $282.00 and gave the stock a “buy” rating in a research report on Wednesday, April 15th. Weiss Ratings raised Ligand Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. Finally, Bank of America started coverage on Ligand Pharmaceuticals in a research report on Wednesday, March 11th. They issued a “buy” rating and a $244.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $256.29.

Get Our Latest Stock Report on LGND

Ligand Pharmaceuticals Company Profile

(Get Free Report)

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.